Just what exactly "ton of news coming" are you referring to? The Ampion run in trial hasn't even been cleared by the FDA to start yet, and who knows when we'll get indications on the ongoing Optina trial. If you're going to post, try to be in the real world with your facts. I am a big holder of AME, but you're not doing anyone any favors by posting innuendo.
same pattern almost every day - around 10 to 10:30 they step in and knock the price down, where it stays the rest of the trading session. Horrible price action, with shorts completely controlling AMPE.
...taken quite the nosedive the past few days. Company needs to get out there and garner more institutional support & following. Otherwise the shorts can & will continue to drive this lower.
Not to mention Lucentis also. Hopefully AMPE will give us some guidance as to when to expect preliminary results from the Optina trial. If results are good, this stock will be many times higher than it is now.
I think Macaluso is trying hard NOT to dilute current shareholders, of which he, I believe, is the largest. It's hard to argue for dilution, as you are doing. He(Macaluso) wants the share price to go higher as much or more than anyone. If they don't require the funds in the near term, I don't see the point in seeking a large Wall Street firm to conduct a Secondary. Hopefully they get upfront cash on a hopeful Zertane licensing deal, which would negate any need for a Secondary. If things progress as they have been, the share price will eventually work itself higher, and will most likely skyrocket if they have positive preliminary results for Optina.
I do feel the company needs to do a roadshow to get in front of potential institutional investors, something they sorely lack & need to support the stock.
Why don't you call the company and discuss this with them? They actually will take an investor's call.
..now that the Ampion trials have been approved by the FDA to start, it's show time. With this trial & the Optina trial running concurrently, and the Zertane trial expected to start hopefully this or next Quarter, AMPE should start to really run higher. All you need is one of the drugs to work for the stock to be many times higher than it is now. If 2 work, then this stock could move like Medivation or Pharmacyclics.
...the article is a total short biased butcher job. He claims the Phase 3 trial is really a Phase 2, and that all previous drugs for DME took 2 years of testing for approvals. What he fails to mention is that the FDA gave AMPE guidance in designing the trial that he so denigrates. He also states the obvious that no oral drug has ever been approved for DME.
The bottom line is that the results will speak for themselves, and if Optina shows indications of efficacy, the stock will soar well ahead of any final approval.
You should know that AMPE generally releases all their news around 4:00 AM before Markets open.
WLT sealed their own death sentence by grossly overpaying for Western Coal at the peak of the cycle, and taking on enormous debt. Now they are going to have a problem paying that debt. Death Spiral down to $10.00
...WLT signed their own death sentence when they loaded up on way too much debt to buy Western Coal right at the peak of the cycle. Shareholders will eventually be wiped out.
...3,800,000 shares short now. They continue to press their case. AMPE needs a deal for Zertane that will include a decent upfront cash payment + future royalties. That would take care of their immediate needs for cash over the next 12 months and put any talk of a dilutive secondary to bed. That would also take some steam out of the short's case.
The real inflection point for AMPE is when we get preliminary results on the Optina & Ampion trials, both of which will be this year.